Effects of C-type natriuretic peptide on rat cardiac contractility.
1. Natriuretic peptide receptors have been found in different heart preparations. However, the role of natriuretic peptides in the regulation of cardiac contractility remains largely elusive and was, therefore, studied here. 2. The rate of relaxation of electrically stimulated, isolated rat papillary muscles was enhanced (114.4+/-1. 4%, P<0.01) after addition of C-type natriuretic peptide (CNP; 1 microM). Time to peak tension decreased in parallel (88+/-3 and 75+/-2 msec before and 5 min after addition of CNP, respectively, P<0.01). On the other hand, the rate of contraction slowly decreased when CNP was added to the papillary muscles. These results show that CNP displays a positive lusitropic effect associated with a negative inotropic effect. The effects of CNP were mimicked by 8-bromo-guanosine 3',5' cyclic monophosphate. 3. Addition of CNP to isolated adult rat cardiomyocytes, induced a 25 fold increase in guanosine 3',5' cyclic monophosphate (cGMP) levels and stimulated the phosphorylation of phospholamban and troponin I, two proteins involved in the regulation of cardiac contractility. The levels of adenosine 3',5' cyclic monophosphate (cAMP) were not affected by the addition of CNP to the myocytes. The CNP-dependent phospholamban phosphorylation was accompanied by the activation of the sarcoplasmic reticulum Ca2+-ATPase. 4. In summary, CNP exerts a positive lusitropic effect, in rat papillary muscles. The putative mechanism involved in the lusitropism induced by this peptide, a cGMP-dependent enhancement of the rate of relaxation with a slowly developing negative inotropic effect, seems different to that described for catecholamines.
Brusq
J M
JM
Laboratoire Glaxo Wellcome, Centre de Recherches, 25, avenue du Québec, 91951 Les Ulis Cedex, France.
Mayoux
E
E
Guigui
L
L
Kirilovsky
J
J
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000378:metabolism; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology*; D010210:Papillary Muscles / Q000166:cytology / Q000187:drug effects / Q000201:enzymology / Q000502:physiology; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D019210:Troponin I / Q000378:metabolism; D000099211:Phospholamban
D009320:Atrial Natriuretic Factor; D002135:Calcium-Binding Proteins; D000252:Calcium-Transporting ATPases; D000242:Cyclic AMP; D006152:Cyclic GMP; D007545:Isoproterenol; D020098:Natriuretic Peptide, C-Type; D019210:Troponin I; D000099211:Phospholamban; C016276:8-bromocyclic GMP